ReviewCureus2026
Evidence-Based Use of Undenatured Type II Collagen in the Management of Osteoarthritis in the Indian Subcontinent and Southeast Asia: A Narrative Review and an Expert Opinion.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is prevalent in the Indian subcontinent and Southeast Asia, causing pain, reduced mobility, and disability. Genetic, lifestyle, and comorbidity factors contribute to earlier onset and more severe disease than in Western populations. Conventional therapies mainly provide symptomatic relief and are limited by adverse effects, underscoring the need for safe, effective adjuncts. Nutraceuticals, particularly undenatured type II collagen, have emerged as promising options. An evidence-based analysis showed that undenatured type II collagen (40 mg/day) improves pain, stiffness, function, and quality of life in early-to-moderate OA (Grades 1-3), with benefits observed within eight weeks, improved compliance, and non-steroidal anti-inflammatory drug-sparing effects. Comparative evidence favors UC-II® (Lonza Greenwood LLC, USA) over other sources, highlighting the importance of product selection. Expert consensus recommends undenatured type II collagen as a nutraceutical adjunct with physiotherapy for long-term use in responders. Future research should include larger trials, biomarker studies, MRI imaging, and real-world data to confirm disease-modifying potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.